Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) Given Average Rating of “Buy” by Analysts

Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) have been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $4.25.

ATNM has been the topic of a number of analyst reports. Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 4th. Zacks Investment Research downgraded Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 4th. Finally, William Blair initiated coverage on Actinium Pharmaceuticals in a report on Thursday, August 8th. They issued an “outperform” rating on the stock.

Shares of NYSEAMERICAN:ATNM traded down $0.01 on Thursday, reaching $0.21. The company had a trading volume of 545,400 shares, compared to its average volume of 1,092,915. Actinium Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $0.87.

An institutional investor recently raised its position in Actinium Pharmaceuticals stock. Oppenheimer & Co. Inc. raised its position in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 34.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 236,281 shares of the biotechnology company’s stock after purchasing an additional 60,769 shares during the quarter. Oppenheimer & Co. Inc. owned 0.15% of Actinium Pharmaceuticals worth $58,000 at the end of the most recent reporting period.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Recommended Story: Convertible Shares

Analyst Recommendations for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.